TY - JOUR AB - After the publication of the article, the authors noted that they had made an error in the titles and legends of Figs. 1 and 2. OS (Overall Survival) in the title and legend of Fig. 1 should be changed to DFS and Disease-Free Survival. DFS in the title and legend of Fig. 2 should be changed to OS and overall survival. The authors provide the correct figures below. [the original article was published in Experimental and Therapeutic Medicine 9: 1709-1718, 2015; DOI: 10.3892/etm.2015.2351] AD - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China Beijing Oncology Hospital Of Weida TCM, Beijing 100023, P.R. China AU - Li,Nan AU - Zheng,Donghai AU - Xue,Jie AU - Guo,Weixing AU - Shi,Jie AU - Sun,Juxian AU - Lu,Chongde AU - Zheng,Weida AU - Wu,Mengchao AU - Cheng,Shuqun DA - 2015/10/01 DO - 10.3892/etm.2015.2655 EP - 1609 IS - 4 JO - Exp Ther Med KW - primary hepatocellular carcinoma cidan Rhizoma Curcumae cyclooxygenase-2 vascular endothelial growth factor PY - 2015 SN - 1792-0981 1792-1015 SP - 1609 ST - [Corrigendum] Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest T2 - Experimental and Therapeutic Medicine TI - [Corrigendum] Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest UR - https://doi.org/10.3892/etm.2015.2655 VL - 10 ER -